Enteric Nervous System Prion-Like Propagation Blockade

Mechanistic description

Dysbiotic bacteria produce lipopolysaccharides that enhance α-synuclein prion-like propagation from enteric neurons to the CNS via the vagus nerve. Targeted antimicrobial therapy against specific pathogenic strains could interrupt this ascending pathological cascade.

Mechanism / pathway

TLR4, SNCA
→
Toll-like receptor 4 / innate immune signaling
→
neurodegeneration

Evidence for (5)

Recombinant pro-CTSD (cathepsin D) enhances SNCA/α-Synuclein degradation in α-Synucleinopathy models.

PMID:35287553 2022 Autophagy
Autophagy mediates the clearance of oligodendroglial SNCA/alpha-synuclein and TPPP/p25A in multiple system atrophy models.

PMID:35000546 2022 Autophagy
Targeted degradation of SNCA/α-synuclein aggregates in neurodegeneration using the AUTOTAC chemical platform.

PMID:37915239 2024 Autophagy
α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson's disease.

PMID:33682798 2021 JCI Insight
Neuronal activity triggers secretory autophagy to mediate the extracellular release of SNCA/α-synuclein.

PMID:40395520 2024 Autophagy Rep

Evidence against (2)

The microbiome-gut-brain axis in Parkinson disease remains difficult to translate from mechanistic models to causal human intervention evidence.

PMID:35750883 2022 Nat Rev Neurol
Microbiome-based Parkinson therapies are still experimental with unresolved strain selection, endpoint, and clinical efficacy questions.

PMID:39568727 2024 Front Nutr

Evidence matrix

5 supporting 2 contradicting

71% supporting

Supporting

Recombinant pro-CTSD (cathepsin D) enhances SNCA/α-Synuclein degradation in α-Synucleinopathy models. PMID:35287553 · 2022 · Autophagy
Autophagy mediates the clearance of oligodendroglial SNCA/alpha-synuclein and TPPP/p25A in multiple system atrophy models. PMID:35000546 · 2022 · Autophagy
Targeted degradation of SNCA/α-synuclein aggregates in neurodegeneration using the AUTOTAC chemical platform. PMID:37915239 · 2024 · Autophagy
α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson's disease. PMID:33682798 · 2021 · JCI Insight
Neuronal activity triggers secretory autophagy to mediate the extracellular release of SNCA/α-synuclein. PMID:40395520 · 2024 · Autophagy Rep

Contradicting

The microbiome-gut-brain axis in Parkinson disease remains difficult to translate from mechanistic models to causal human intervention evidence. PMID:35750883 · 2022 · Nat Rev Neurol
Microbiome-based Parkinson therapies are still experimental with unresolved strain selection, endpoint, and clinical efficacy questions. PMID:39568727 · 2024 · Front Nutr

Top-ranked evidence

trust_score × relevance_score × exp(-recency_weight × recency_days / 365)

Supports · top 3

#1 paper-bfff65c8371d 0.463 trust 0.50 · rel 1.00 · 92d
#2 paper-704eb9e3ff22 0.463 trust 0.50 · rel 1.00 · 92d
#3 paper-e3fbef5eb273 0.463 trust 0.50 · rel 1.00 · 92d

42 total ranked · scidex.hypotheses.evidence_ranking

Cite this hypothesis

Citation

etl-backfill (2026). Enteric Nervous System Prion-Like Propagation Blockade. SciDEX hypothesis. https://prism.scidex.ai/hypotheses/h-2e7eb2ea

BibTeX

@misc{scidex_hypothesis_h2e7eb2e,
  title        = {Enteric Nervous System Prion-Like Propagation Blockade},
  author       = {etl-backfill},
  year         = {2026},
  howpublished = {SciDEX hypothesis},
  url          = {https://prism.scidex.ai/hypotheses/h-2e7eb2ea},
  note         = {SciDEX artifact hypothesis:h-2e7eb2ea}
}